Related Experiment Video
Updated: Aug 17, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Radiotherapy for the treatment of locally recurrent cervical cancer
1Department of Radiation Oncology, Delaware County Memorial Hospital, Drexel Hill, PA 19026-1186, USA.
Abstract:
Following radical hysterectomy for stage I-IIA cervical carcinoma, 10%-15% of women will have a recurrence. Sixty percent of these recurrences will be located in the pelvis alone. The treatment of a localized pelvic recurrence depends on a number of factors, but primarily the history of previous radiation therapy (RT) to the pelvis and the location of the recurrence. For patients without a history of prior treatment, RT with or without chemotherapy can lead to disease-free survival rates of 20%-50% and local control rates of 20%-60%, and should be considered first-line treatment. For those with a history of previous RT and sidewall or nodal recurrences, a combination of surgery and brachytherapy or intraoperative radiotherapy may improve survival for these women who were previously considered incurable. However, this requires special expertise and technology not available at most centers.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Tumor Immunotherapy